SoftBank, RA keep pumping money into biotech startups as protein degradation player bags $102M
On the heels of a $500 million biobucks deal with Amgen a few weeks ago following the appointment of former Astellas CBO Percival Barretto-Ko as their new CEO in November, TPD startup Plexium is on a money spree. And today the biotech has nabbed a big B round from some marquee biotech backers.
The startup said it closed the round with $102 million, which Barretto-Ko told Endpoints News will last the company 2-3 years. The syndicate includes a few A-list investors on board, including SoftBank, RA Capital and Surveyor Capital. California-based investors BVF Partners and TCG X led the round, with TCG X partner Cariad Chester now a member of Plexium’s board.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.